Table 1.

Characteristics of studies included in the meta-analysis

Study			Age (years) mean ± SD	Male sex n (%)	DOACs drug	Comparator	Follow-up (months)	Cancer patients (%)	Main efficacy outcome	Main safety outcome	Phase	Study design
Type	Name	Year
Thromboprophylaxis	MAGELLAN [24]	2013	NR	NR	Rivaroxaban	Enoxaparin	3 months	7.3%	Composite of asymptomatic proximal DVT, symptomatic proximal or distal DVT, symptomatic nonfatal PE, and death from VTE	Clinically relevant bleeding	Phase 3	Subgroup analysis
	APEX [14]	2016	76.8 ± 9.3	240 (48.1)	Betrixaban	Enoxaparin	1 month	12.8%	Composite of asymptomatic proximal DVT, symptomatic proximal or distal DVT, symptomatic nonfatal PE, or fatal PE	Major bleeding	Phase 3	Subgroup analysis
	CASSINI [12]	2019	63a	222 (52.9)	Rivaroxaban	Placebo	6 months	100%	Composite of symptomatic or asymptomatic proximal DVT in a lower limb, symptomatic DVT in an upper limb or distal DVT in a lower limb, symptomatic or incidental PE, and death from VTE	Major bleeding	Phase 3	RCT
	AVERT [13]	2019	61.2 ± 12.4	121 (41.6)	Apixaban	Placebo	6 months	100%	VTE	Major bleeding	Phase 3	RCT
Treatment	SELECT-D [16]	2018	67a	116 (57)	Rivaroxaban	Dalteparin	24 months	100%	Recurrent VTE	Major bleeding	Pilot	RCT
	Hokusai VTE Cancer [17]	2018	64.3 ± 11	277 (53.1)	Edoxaban	Dalteparin	12 months	100%	Recurrent VTE	Major bleeding	Phase 3	RCT
	ADAM VTE [7]	2019	64.4 ± 11.3	72 (48)	Apixaban	Dalteparin	6 months	100%	Recurrent VTE	Major bleeding	Phase 3	RCT
	Caravaggio [15]	2020	67.2 ± 11.3	292 (50.7)	Apixaban	Dalteparin	7 months	100%	Recurrent VTE	Major bleeding	Phase 3	RCT

Abbreviations: DOAC direct oral anticoagulant, DVT deep vein thrombosis. PE pulmonary embolism, VTE venous thromboembolism, RCT randomized clinical trial

^a Median age